Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo-controlled clinical trial.

Background: Heart disease is an important cause of morbidity and mortality in cats, but there is limited evidence of the benefit of any medication.

Hypothesis: The angiotensin-converting enzyme inhibitor benazepril would delay the time to treatment failure in cats with heart disease of various etiologies.

Animals: One hundred fifty-one client-owned cats.

Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs.

To support their combined use, the objective of the study was to evaluate the effects of benazepril and pimobendan on serum angiotensin-converting enzyme (ACE) activity in dogs. A total of 48 healthy beagle dogs were randomized into four groups (n = 12 per group) in a parallel-group design study: A (control, placebo twice daily (BID)); B (0.5-1.

Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial.

Background: Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs.

Objective: To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD.

Animals: Forty-nine client-owned dogs with CKD.

Safety of a benazepril and pimobendan combination tablet in adult healthy dogs.

The objective of the study was to investigate the safety of a combination tablet of benazepril and pimobendan, Fortekor PLUS , in a randomized, blinded, parallel-group design study in healthy adult beagle dogs. The test article, Fortekor PLUS tablets, was administered orally twice daily for 6 months at one, two, and four times the highest recommended dosage of 0.5 mg/kg benazepril hydrochloride/0.